PEPGEN INC. Debt Securities, Available-for-sale, Amortized Cost
PEPGEN INC. (PEPG) had Debt Securities, Available-for-sale, Amortized Cost of $94.56 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $94.56M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $90.18M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $87.90M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $20.89M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $94.56M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $90.18M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $87.90M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $20.89M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $39.60M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $54.19M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $70.73M 10-K · filed 2026-03-04 |
| 2024-09-30 | $96.44M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $95.28M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $41.39M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $29.62M 10-K · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |